Dr. Giovanni Gaudino Explains His Clinical Trials on Mesothelioma Patients

Dr. Giovanni Gaudino is an Italian biochemist and molecular biologist who researches the molecular mechanisms of asbestos and its relationship to the development of mesothelioma. In addition to his laboratory research in Italy, Dr. Gaudino conducts mesothelioma research in the United States as a visiting scholar at the Cancer Research Center of Hawaii (CRCH). Currently, Dr. Gaudino is conducting a clinical trial in Italy on mesothelioma patients using Gemcitabine in combination with a different drug, Imatanib Mesylate (trade name Gleevec).



Dr. Gaudino was born in Saronno, a town in northern Italy. His background is in basic science. He earned his M.S. (U.S. equivalent) in Biological Sciences and his Ph.D. (U.S. equivalent) in biochemistry from the University of Torino in northern Italy. He is currently a full professor of molecular biology in the School of Pharmacy and DISCAFF at the University of Piemonte Orientale “A. Avogadro” in Novara, Italy. Dr. Gaudino is a member of the American Society of Biochemistry and Molecular Biology (ASBMB), the Italian Federation of Life Sciences (FISV), the Italian Society of Biophysics and Molecular Biology (SIBBM), and the Italian Group Mesothelioma (GIMe). Dr. Gaudino summed up his involvement in the area of cancer research by saying,

“I came to cancer research almost by chance . . . . This was almost 30 years ago, I have to say. And it was the right choice, because that field, the field of molecular biology of cancer, is a very important field. And so now I’m very glad that I dedicated all, basically all my professional life, . . . to identify the molecular mechanisms of cancer.”

In 2008, Dr. Giovanni Gaudino came from Italy to join Dr. Michele Carbone’s team of research scientists as a visiting scholar at the CRCH. In the time that he has been a part of the research team at the Center, he has come to appreciate the quality of care offered by the clinicians and other physicians who treat the patients. He calls the oncologists “special M.D.s in my team” because they are sensitive to their patients.

Galiher DeRobertis Waxman had the privilege of talking with this humble and dedicated scientist about his work at the CRCH – the breakthrough in research that has led to his work with a new combination of drugs and new hope for mesothelioma patients – and his hopes for cancer research and the future of the Center. He sat down with our attorneys and gave an interview in which he shared his thoughts with us on the importance of this research, of clinical trials, and of collaboration among scientists and the “multidisciplinary approach” in “working towards a cure.”